2&#39;-substituted thiazolo[5&#39;, 4&#39;-16, 17] steroid of androstane series



United States Patent 3,119,816 2'-SUBSTITUTED THIAZOLO[5',4'-16,17]STERID OF ANDROSTANE SERES Taichiro Komeno, Sumiyoshi-ku, Osaka-shit, Japan, assignor to Shionogi & Co., Ltd., Osaka, .iapan No Drawing. Filed Dec. 17, 1962, Ser. No. 244,877 Claims priority, application Japan Dec. 19, 1961 1 13 Claims. (Cl. 260-2395) This invention relates to thiazolosteroid-s and production thereof. More particularly, it relates to thiazolo- [5 ',4'-16,17]androstancs and production thereof.

The said thiazolo[5',4'-16,l7]androstanes are intended to mean the steroids having the partial structural formula:

jeots will be apparent to those conversant with the art to which the present invention pertains from the subsequent description.

The process of the present invention is representable by the following partial formula scheme showing only the D-ring of the steroid skeleton:

wherein X is a halogen atom (e.g. chlorine, bromine, iodine), R is a hydrogen atom, a lower alkyl group (e.g. methyl, ethyl, propyl), an amino group or a lower alkoxy group (e.g. methoxy, ethoxy, propoxy) and the ripple mark (2) represents uor ,B-configuration.

The process of the present invention is generally applicable to 16-halogenm17-oXo-steroids of the androstane series having the partial structure of Formula II. Thus, the starting material of the present invention may be 16-chloro 17 oxo-steroids, 16-bromo-17-oxo-steroids or 16-iodo-17-oXo-steroids of androstane series. The steric configuration of the halogen atom on the D-ring of the starting material has substantially no efiect on the reac tion; that is, the halogen atom may have 00- or B-configuration. Furthermore, such a substituent which does not exert any substantial efiieot on the reaction, as 3- hydroxyl and ll-oxo group, may exist at any position ice on the A-, B- or C-ring of the starting material. Examples of 16-halogeno-17-oxo-steroids available as the starting compound include 30t-hydI'0Xy-l60t-Chl0I'O-l7-OXO- 55 and-rostane, 3a-hydroxy-16u-brom0-17-oxo-5fl-androstane, 35 hydroxy-la-bromo-l7-oxo-5a-androstane, 3ahydroxy-16(3-bromo-l7-oXo-5B-androstane, 36 hydroxy- 16 3 bIOIIlO-17-0XO-50L-3I1d105i3116, 3/3-l1YClIOXY-l6a-i0d0- 17-0X0-5oc-3I1dl'05ta116, 3fl-hydroxy 16a ch1oro-17-0Xo- 5(6)-androstene, 3a-hydroxy 16a bromo-l7-oxo-S(6)- androstene, 3B hydroXy-16oz-bromo-l7-oxo-5(6)-androstene, 3a-hydroXy-16,B-bromo 17 oXo-5(6)-androstene, 3B hydroxy-l6B-br0mo-17-oXo-5(6)-androstene, 3a-hydroXy-16B-iodo-l7-oXo-5 (6 -androstene, 3,17-di0XO-16occhloro Sfi androstene, 3,l7-dioxo-16a-bromo-5a-androstane, 3,17-dioxo-16a-bromo-5/3-androstane, 3,17 dlOX0- 16B bromo 50c androstane, 3,17-dioXo-l6[3-bromo-5B- androstane, 3,17-dioxo 16a chloro-4-androstene, 3,17- dioxo-16a-bromo-4-androstene, 3,17-dioxo-165-bromo-4- androstene, 3u-acetoxy-161x-chloro-17-oxo-5fi-androstane, 3a-acetoxy-16oc-bromo-l7-oxo-5 8-audrostane, 3cx-PI'0POXY- l6u-bromo-17-oX0-5B-androstane, 3fi-acetoXy-16a-bromo 17-oXo-5a-androstane, 3;? but-oxy-16a-bromo-l7-oxo-5aandrostane, 3a-acetoxy-l6,8-bromo-17-oxo-5B-androstane, 3fi-acetoxy-1GB-bromo-l7-oxo-5u-androstane, 3B-acetoxyc-l0d0 17 oxo-5a-androstane, 3,6-acetoXy-16u-chloro- 17-oxo-5(6)-androstene, 3oz acetoxy-l6ot-bromo-l7-oxo- 5(6)-androstene, 3a-propoxy 16oz bromo-17-oxo-5(6)- tandrostene, BB-acetoxy 160a bromo-17-oxo-5(6)-androstene, 3/9-propoXy-16a-bromo 17 oXo-5(6)-androstene, 3/3 butoxy-l6a-bromo-17-oXo-5(6)-androstene, 3u-acetoxy-16fl-bromo-l7-oXo-5 (6) -androstene, 3 B-acetoxy- 1 619- br0mo-17-oXo-5 6) -androste11e, 3 a-acetoXy-16B-iodo-l7- oxo 5(6) androstene, 3,3-ethylenedioXy-16a-cl1loro-17- oxo-SB-androstane, 3,3-ethylenedioxy- 1 6a-bromo- 17 -oxo- 5a-androstane, 3,3 ethylenedioxy-lSet-bromo-l7-oxo-5B- androstane, 3,3 ethylenedioxy 163 bromo-l7-oxo-5aandrostane, 3,3 ethylenedioxy 16B bromo-17-oXo-5B- androstane, 3,3-ethylenedioxy 16oz ch1oro-17-oXo-5(6)- androstene, 3,3-ethylenedioxy 16cc bromo-l7-oxo-5(6)- androstene, 3,3-ethylenedioxy 16,8 br0mo-l7-oXo-5(6)- androstene, 3,11,17-trioxo-l6a-bromo-4-androstene, 3,11, l7-trioxo-16 8-bromo 4 androstene, 3,17-dioxo-11fl-hydroxy-l6,8-bromo-4-androstene, etc. These 16-halogeno- 17-oXo-steroids of the androstane series are known and/ or can be prepared according to conventional methods [e.g. I. Fried et al.: US. Patent Nos. 2,857,403 and 2,831,872; B. Ellis et al.: J. Chem. Soc., 800 (1958); J. Fajko et al.: Chemical Abstracts, 53, 4349 (1959)].

The reagents to be condensed with the said l6-halogeno- 17-oXo-steroids are the thiocarbamoyl compounds representable by the formula:

R( 3 NH (III) wherein R has the same significance as designated above, which include thioformamide, thio(lower)alkanoylamide (e.g. thioacetamide, thiopropionamide), thiourea, lower alkyl thiocarbamate (e.g. methyl thiocarbamate, ethyl thiocarbamate), etc.

The process of the present invent-ion comprises condensing the 16-halogeno-17-oXo-steroid of the androstane series having the partial structure of Formula II with the thiocarbamoyl compound of Formula III in an inert organic solvent (erg. methanol, ethanol, propanol). The

reaction temperature may be selected on the basis of the starting materials and reagents. A relatively high temperature such as reflux -or more than 100 C. is usually needed. Depending on the kind of the employed thiocarbamoyl compound the condensation reaction may proceed incompletely. For instance, when thiourea is employed as a reagent, there is obtained not the objective thiazolo[,4'-16,l7]androstane having the partial structure of Formula I but the intermediate thereto as the result of said condensation reaction. In such case, with or without the previous separation of the intermediarily produced compound from the reaction mixture, the intermediate may be treated with an alkali (e.g. potassium hydroxide, sodium hydroxide) to obtain the objective thiazolo[5',4'-l6,17]androstane having the partial structure of Formula 1'. These thiazolo[5',4'-16,17] androstanes may be secondarily subjected to a per se conventional reaction for converting the substituent on the thiazole nucleus into another substituent.

The thus-produced thiazolo[5',4-16,17]androstanes having the partial structure of Formula I include, for example, 2'-methylthiazolo[5,4'-16,17]androsta-5,l6-dien-3fl-ol, 2'-ethylthiazolo[5 ',4- 16, 17 androsta-S, 1 6-dien-3 ,8- ol, 2'-propylthiazolo[5',4-16,17] androsta-S,16-dien-313-ol, 2-methylthiazolo[5,4-16,17]androsta5,16 dien-3 a-Ol, 2'-ethylthiaz0lo[5',4-16, 17] androsta-S, l6-dien-3 a-Ol, 2'-methylthiazolo [5',4'-16,17]androsta-5,16-dien-3 fl-ol acetate, 2-ethy1thiazolo [5',4'-16,17] androsta-S, 16-dien-3 fl-ol 3-propionate, 2-methylthiazolo[5',4-16,17]androsta-4,16-dien-3-one, 2-ethy-lthiazolo[5',4'-16,17]androsta-4, 1 6-dien-3-one, 2-ethylthiazolo [5',4'-16,17] androst-16-en-3 -one, 2-methylthiazolo[5,4'-16,17]androst-16-en-3-one 3,3-

ethyleneketal, thiazolo[5,4'-16,17]androsta-5,16-dien-3m-ol, thiazolo[5,4-16,17]androsta-4,16-dien-3-one, 2-aminothiazolo[5,4-16,17]androst-16-en-3-one, 2-arninothiazolo [5',4'-16, 17] androsta-S, 1 6-dien-3 3-01, 2'-aminothiazolo[5',4'-16,17] androsta-5,16-dien-3a-ol, 2'-acetylaminothiazolo[5',4'-16,17]androsta-5,16-dien- 313-01 3-acetate, 2'-propionylaminothiazolo [5 ,4'-16,17]andr0sta-5, 1 6- dien-3a-ol 3-propionate, 2'-acetylaminothiazolo[5,4'-16,17]androsta-4,16-dien- 3-one, 2'-.propionylaminothiazolo[5',4'-16,17]androsta-4,16-

dien-3-one, 2'-methoxythiazolo [5',4'-16,'17]androsta-4,16-dien-3- one, 2'ethoxythiazolo[5',4-16,17]androsta-4,16-dien-3 -one, 2-methoxythiazolo[5,4'-16,17]androsta-5, l6-dien-3}3- o1, 2'-methoxythiazolo[5',4-l6,17]androsta-5,16-dien- Sfl-ol S-acetate, 2methoxythiazolo [5',4'-l6,17] androsta-4,16-dien- 3,11-dione, etc.

These thiazolo[5',4'-16,17]androstanes having the partial structure of Formula I are generally useful as antagonists to hormonic substances. For example, a representative compound prepared by the process of the present invention, 2'-methylthiazolo[5',4-16,17]androsta- 4,16-dien-3-one produces inhibition of gonadotropin secretion without showing any androgenic response in the castrated male rat which received a total of milligrams. Accordingly, the compound is useful as (1) controlling agent tor diseases of menopause; (2) ovulationinhibition agent or contraceptive agent; and (3) controlling agent for hypergonadisrn or precocious puberty. Animal test data, e.g. with the rat, establish that the other compounds of the present invention also show specific activities. For instance, 2-aminothiazole[5',4- 16,17]androsta-5,16=dien-3-ol possesses a Na-excreting action and 2-acetylaminothiazolo[5,4-16,17]andr0sta- 4,16-dien-3-one shows a Na-retaining activity.

The following examples set forth illustratively presently-prefei'red embodiments of the invention. In these examples, mg.=milligram(s), g.= gram(s), and ml.=mi1lilitre(s Other abbreviations each have a conventional meaning.

EXAMPLE 1 Preparation of 2'-Methylthiazolo[5,4',-16,17]Andr0sta- 5,16-Dien-3fl-0l 3-Acetate A solution of 313-aoetoxy-16B-bromo-5-androsten-17- one [B. Ellis et al.: J. Chem. Soc., 800 (1958)] (730 mg.) and thioacetamide (800 mg.) in anhydrous ethanol (20 ml.) is put in a sealed steel-tube and heated for 35 hours in an oil bath at C. The reaction mixture is diluted with water and shaken with ether. The ether extract is washed with an aqueous solution of sodium carbonate and water in turn, dried over anhydrous sodium sulfate and evaporated to dryness. The residue (759 mg.) is chromatographed on alumina (20 g). The eluates with a mixture of petroleum ether and benzene (4:1 to 1:1) are combined together, evaporated and crystallized from methanol to give 2-methylthiazolo[5', 4'-16,17]androsta-5,16-dien-3p3-ol 3-acetate (304 mg.) as plates melting at to 192 C. [a 39.5 :2 (in chloroform) Analysis.Calcd. for C23H31O2NS: c, 71.65; H, 8.10;

EXAMPLE 2 Preparation of Z-Methylthiazolo [5,4-16,17]Andr0sta- 5,16-Dien-3/3-0l N=I-CHI 3,6-hydroxy 1618 bromo-5-androsten-17-one [B. Ellis et al.: J. Chem. Soc., 800 (1958)] is reacted with thioacetamide in anhydrous ethanol and treated as in Example 1 to obtain 2'-methylthiazolo[5',4-16,1 7]androsta- 5,16-dien-3B-ol as crystals melting at 200 to 202 C. (decomp.). [ed -55.9 14 (in chloroform).

U.V.: im 260 my. (62 5,480). 1.1%.; page cmf 3334; 5

Analysis.-Calcd. for C H ONS: C, 73.42; H, 8.51; N, 4.08; S, 9.33. Found: C, 73.72; H, 8.89; N, 3.99; S, 9.41.

The 2'-methylthiazol-o[5',4-16,17]androsta 5,16-dien- 3B-ol is also prepared by hydrolyzing 2-methylthiazolo- [5',4'-16,17] androsta 5,16 dien-SB-ol S-acetate obtained in Example 1 with an alkaline substance. Thus, a solution of 2-methylthiazolo[5',4-l6,17]androsta-5,16- dien-Bfi-ol 3-acetate (240' mg.) and potassium carbonate (300 mg.) in a mixture of methanol ml.) and water (3 ml.) is refluxed for 30 minutes. The reaction mixture is diluted with Water and the precipitated crystals are collected by filtration, dried and recrystallized from methanol to give 2-methy1thiaz0lo[5,446,17]androsta- 5,16-dien-3B-ol (210 mg.).

In the similar manner, there are obtained other 2'-lower alkylthiozolo[5,4'-16,l7]androsta 5,16 d-ien 3B ols such as 2 methylthiazolo[5',4-16,17]androsta 5,16- dien-3fi-ol and 2-ethylthiazolo[5,4'-16,17]androsta-5,16- dien-Sfi-ol.

EXAMPLE 3 Preparation of 2'-Methylthiaz0l0[5,4-16,17]Andr0sta- 4,16-Diert-3-One N:|CH3

16B-brorno 4 androstene-3,1 7-dione [1. Fajkos et 211.: Chemical Abstracts, 53, 4349 (1959)] is reacted with thioacetamide in anhydrous ethanol and treated as in Example 1 to obtain 2'methylthiazolo[5',4-16,'1 7]androsta 4,16 diene-3-one as plates melting at 203 to 205 C. (decomp.). [M +906 12 (in chloroform).

Analysis.Calcd. for C H ONS: C, 73.85; H, 7.97; N, 4.10; S, 9.39. Found: C, 73.94; H, 8.23; N, 3.98; S, 9.20.

The 2' methylthiazolo[5,4-16,17]androsta-4,l6-dien- 3-one is also prepared by subjecting 2-methylthiazolo- [5,4'-16,17]androsta 5,16 dien 3,8 01 obtained in Example 2 to Oppenauer oxidation. Thus, a solution of 2- methylthiazo1o[5,4-l6, 17]androsta 5,16 dien-3/3-ol (155 mg.) in .a mixture of toluene (10 ml.) and cyclohexanone (1 ml.) is distilled .to about /4 volume for removal of water in the solution. While the distillation is continued, a solution of aluminum isopropoxide (100 mg.) in toluene (5 ml.) is added to the distilling solution. Then, the distillation is further continued mildly for 1 hour. To the reaction mixture, there is added an aqueous solution of potassium sodium tartrate, and the resultant mixture is shaken with ether. The ether extract is washed with water, dried and evaporated to dryness. The residue is crystallized from acetone to give 2-methylthiazolo[5', 4'-16,17]androsta 4,16 dien 3 one (105 mg.).

In similar manner, there are obtained other 2-loWer alkylthiazolo[5',4'-16,l7]androsta 4,16-dien-3-0nes such as 2'-ethylthiazolo[5',4'-16,17]androsta 4 16 dien-3- one and 2'-propytlthiazolo[5',4'-16,17] androsta 4,16- dien-3-one.

6 EXAMPLE 4 Preparation of 2-Amin0thiaz0l0[5',4'-16,17]Andr0sta- 5,16-Dien-3fl-Ol A solution of 3fl-acetoxy-l6fi-bromo 5 androsten-1 7- one (6. 00 g.) and thiourea (2.25 g.) in anhydrous ethanol (30 ml.) is refluxed for 27 hours. To the reaction mixture, there is added water, and the precipitate is collected by filtration, washed with water and dried. The collected substance is heated on a steam bath with potassium hydroxide (7 g.) in methanol (70 ml.) for 30 minutes. To the resulting mixture, there is added water, and the precipitated crystals are collected by filtration, washed with water, dried and recrystallized from a mixture of chloroform and ethanol to give 2-aminothiazolo[5,4'-' 16,17]androsta-5,16-dien-3p3-ol (4.27 g.) as fine needles melting at 268 to 270 C. (decomp.). '-35.3 12 (in pyridine).

Analysis.-Calcd. for C H ON S: C, 69.72; H, 8.19; N, 8.13; S, 9.31. Found: C, 69.63; H, 8.33; N, 8.38; S, 9.35

EXAMPLE 5 Preparation of 2Acetylaminothiazolo[5',4-16,17] Androsta-5,16-Dien-3fl-0l 3-Acetate PU .QU

NHCOCH:

EXAMPLE 6 Preparation of 2'-Amin0thiaz0l0 [5 ',4'-1 6,1 7] A ndrosta-4,1 6-Dien-3-One 65* m .QU -QU 16fl-bromo-4-androstene-3,17-dione [1. Fajko et al.: Chemical Abstracts, 53, 4349 (1959)] is reacted with thiourea in anhydrous ethanol and treated as in Example 4 to obtain 2'-aminothiazolo[5',4-16,17]androsta-4,16- dien-3-one as yellow needles melting at 271 to 273 C. (decomp.). [M +1193 1:2 (in pyridine).

U.V.: xggr 242 my. (6: 19,360). I.R.: 1 2:2 cm. 3452; 3290; 3202; 3178; 1676; 1622; 1540; 1517; 864. 11:3 Cm.1 3662; 3548; 3426; 1663; 1605; 1506; 863

Analysis.Calcd. for C H ON S: C, 70.13; H, 7.65; N, 8.18; S, 9.46. Found: C, 69.69; H, 7.84; N, 8.27; S, 9.32.

The 2-aminothiazolo[5,4-16,17]androsta-4,16-dien-3- one is also prepared by subjecting 2'-aminothiazolo[5,4- 16,17]androsta-5,16-dien-3fi-ol obtained in Example 4 to Oppenauer oxidation. Thus, a solution of 2'-aminothiazolo[5,4'-16,17]androsta-5,16-dien-3fi-ol (2.74 g.) and aluminum isopropoxide (2.00 g.) in a mixture of dioxane (50 ml.), toluene (50 m1.) and cyclohexanone (15 ml.) is refluxed for 4 hours. After cooling, the reaction mixture is mixed with a. saturated aqueous solution of potassium sodium tartrate and steam distilled for 1 hour. The precipitate is collected by filtration, washed with water, dried and crystallized from a mixture of chloroform and ethanol to give 2-aminotl1iazolo[5,4'-16,17]androsta- 4,16-dien-3-one (2.38 g.).

EXAMPLE 7 Preparation of 2-A cetylaminothiazolo [5 ,4 '-1 6,1 7 Andr0sta-4,16-Dien-3-0ne NZI-NHCOCHa W 2' aminothiazolo[5',4' 16,17]androsta 4,16 dien- 3-one is acetylated with acetic anhydride in pyridine in a. conventional manner and the resulting product is crystallized from methanol to give 2'-acetylaminothiazolo[5,4- 16,17] androsta-4,16-dien-3-one as colorless needles melting at 282 to 284 C. (decomp.). [M +113.2 :2 (in pyridine).

U.V.: kfiiflf 241 m (6: 18,800); 287 m (e: 11,430). LR: 1123;? cm." 3230; 3068; 1694; 1665; 1616; 1552 Analysis.Calcd. for C H O N S: C, 68.72; H, 7.34; N, 7.29; S, 8.24. Found: C, 68.71; H, 7.46; N, 7.38; S, 8.55. 1

In similar manner, there are obtained other 2'-lower alkanoylaminothiazolo[5,4 16,17] androsta 4,16-dien- 3-ones such as 2'-propionylaminothiazolo[5',4'-l6,17] androsta-4,16-dien-3-one and 2-butyrylaminothiazolo[5', 4'-16,17]androsta-4,16-die11-3-one.

What is claimed is:

1. A thiazolosteroid of the formula l l j wherein R is a member selected from the group consisting of H, lower alkyl, amino, lower alkanoylamino and lower alkoxy, A is a member selected from the group consisting of hydroxymethylene, lower alkanoyloxymethylene and carbonyl, and a double bond is present between the 5- position and the adjacent position thereto.

2. 2' lower a1kylthiazolo[5,4' 16,17]androsta.- 5,16-dien-3/8-ol 3-lower alkanoate.

3. 2 methylthiazolo[5,4 16,17]androsta 5,16- dien-3fi-ol 3-acetate.

4. 2' lower a1kylthiazolo[5',4' 16,17]androsta- 5,16-dien-3/i-ol.

5. 2' methy1thiazolo[5',4' 16,17Jandrosta 5,16- dien-Bfi-ol.

6. 2 lower alky1thiazo1o[5',4' 16,17] androsta 4,16- dien-S-one.

7. 2 methylthiazolo[5',4' 16,17]androsta 4,16- dien-3-one.

8. 2' aminothiazolo[5',4 16,17]androsta 5,16- dien-3B-ol.

9. 2' lower alkanoylaminothiazolo[5,4' 16,17] androsta-5,16-dien-3 8-ol 3-lower alkanoate.

10. 2 acetylaminothiazolo[5,4' 16,17]androstaa 5,16-dien-3,B-ol 3-acetate.

11. 2 aminothiazolo[5',4 16,17]androsta 4,16- dien-3-one.

12. 2' lower alkanoylaminothiazolo[5,4' 16,17] androsta-4,16-dien-3-one.

13. 2 acetylaminothiazolo[5',4' 16,17] androsta 4, 16-dien-3-one.

No references cited. 

1. A THIAZOLOSTEROID OF THE FORMULA 